Skip to main content
SpringerLink
Log in

Circulating Biomarkers in Heart Failure

  • Chapter
  • First Online:
Heart Failure: From Research to Clinical Practice

Part of the book series: Advances in Experimental Medicine and Biology ((AIM,volume 1067))

Abstract

Biological markers have served for diagnosis, risk stratification and guided therapy of heart failure (HF). Our knowledge regarding abilities of biomarkers to relate to several pathways of HF pathogenesis and reflect clinical worsening or improvement in the disease is steadily expanding. Although there are numerous clinical guidelines, which clearly diagnosis, prevention and evidence-based treatment of HF, a strategy regarding exclusion of HF, as well as risk stratification of HF, nature evolution of disease is not well established and requires more development. The aim of the chapter is to discuss a role of biomarker-based approaches for more accurate diagnosis, in-depth risk stratification and individual targeting in treatment of patients with HF.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ADM:

adrenomedullin

ANP:

atrial natriuretic peptide

ARNI:

angiotensin receptor neprilysin inhibitors

BNP:

brain natriuretic peptide

BRPs:

bone related proteins

cGMP:

cyclic guanylyl monophosphate

CITP:

carboxy-terminal telopeptide

CNP:

C-type natriuretic peptide

CRP:

C-reactive protein

CT-proET-1:

C-terminal-pro-endothelin-1

CV:

cardiovascular

EMPs:

endothelial microparticles

EPCs:

endothelial progenitor cells

Gal-3:

galectin-3

GDF-15:

Growth differentiation factor-15

HF:

heart failure

hFABP:

heart type of fatty acid binding protein

HFpEF:

heart failure with preserved ejection fraction

HFrEF:

heart failure with reduced ejection fraction

LV:

left ventricular

MMP:

matrix metalloproteinase

MPs:

micro particles

MR-proANP:

mid-regional pro-atrial natriuretic peptide

MR-proADM:

mid-regional pro-adrenomedullin

NPs:

natriuretic peptides

NT-proBNP:

NT-pro-brain natriuretic peptide

PICP:

carboxy-terminal propeptide

sST2:

soluble suppressor of tumorigenicity-2 receptor

References

  • AbouEzzeddine OF, McKie PM, Dunlay SM, Stevens SR, Felker GM, Borlaug BA et al (2017) Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction. J Am Heart Assoc 6(2). https://doi.org/10.1161/JAHA.116.004382

    Article  PubMed  PubMed Central  Google Scholar 

  • Agnello L, Bivona G, Sasso BL, Scazzone C, Bazan V, Bellia C et al (2017) Galectin-3 in acute coronary syndrome. Clin Biochem. https://doi.org/10.1016/j.clinbiochem.2017.04.018. [Epub ahead of print]

  • Aimo A, Vergaro G, Ripoli A, Bayes-Genis A, Pascual Figal DA, de Boer RA et al (2017) Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure. JACC Heart Fail 5(4):287–296

    Article  PubMed  Google Scholar 

  • Amin A, Chitsazan M, Shiukhi Ahmad Abad F, Taghavi S, Naderi N (2017) On admission serum sodium and uric acid levels predict 30 day rehospitalization or death in patients with acute decompensated heart failure. ESC Heart Fail 4(2):162–168

    Article  PubMed  PubMed Central  Google Scholar 

  • Anguita M (2017) High-sensitivity troponins and prognosis of heart failure. Rev Clin Esp 217(2):95–96

    Article  CAS  PubMed  Google Scholar 

  • Aspromonte N, Gulizia MM, Clerico A, Di Tano G, Emdin M, Feola M et al (2016) ANMCO/ELAS/SIBioC consensus document: recommendations for the use of cardiac biomarkers in heart failure patients. G Ital Cardiol (Rome) 17(9):615–656

    Google Scholar 

  • Bayes-Genis A, Ordonez-Llanos J (2015) Multiple biomarker strategies for risk stratification in heart failure. Clin Chim Acta 443:120–125

    Article  CAS  PubMed  Google Scholar 

  • Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J et al (2014) Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol 63(2):158–166

    Article  CAS  PubMed  Google Scholar 

  • Berezin AE (2014) Serum uric acid as a metabolic regulator of endothelial reparative processes in heart failure patients. Stem Cell Transl Invest 1(1):1–5

    Google Scholar 

  • Berezin AE (2015a) Biological markers of cardiovascular diseases. Part 4. Diagnostic and prognostic value of biological markers at risk stratification among patients with heart failure. LAMBERT Academic Publishing GmbH, Moscow. 329 p

    Google Scholar 

  • Berezin AE (2015b) The risk stratification in heart failure patients: the controversial role of high-sensitive ST2. J Integr Cardiol 1(6):216–217

    Google Scholar 

  • Berezin A (2015c) Endothelial derived micro particles: biomarkers for heart failure diagnosis and management. J Clin Trial Cardiol 2(3):1–3

    Article  Google Scholar 

  • Berezin AE (2015d) Impaired pattern of endothelial derived microparticles in heart failure patients. J Mol Genet Med 9:1. https://doi.org/10.4172/1747-0862.1000152

    Article  CAS  Google Scholar 

  • Berezin AE (2016a) Prognostication in different heart failure phenotypes: the role of circulating biomarkers. J Circ Biomark 5:01. https://doi.org/10.5772/62797

    Article  CAS  Google Scholar 

  • Berezin A (2016b) Biomarkers for cardiovascular risk in diabetic patients. Heart 102(24):1939–1941

    Article  CAS  PubMed  Google Scholar 

  • Berezin AE (2016c) Impaired phenotype of endothelial cell-derived micro particles: the missed link in heart failure development? Biom J 2(2):14–19

    Google Scholar 

  • Berezin A (2016d) Epigenetics in heart failure phenotypes. BBA Clinical 6:31–37

    Article  PubMed  PubMed Central  Google Scholar 

  • Berezin AE (2016e) Epigenetically modified endothelial progenitor cells in heart failure. J Clin Epigenet 2(2):21–23

    Google Scholar 

  • Berezin AE (2016f) Genetic predictive scores in heart failure: possibilities and expectations. J Data Mining Genomics Proteomics 7(5):e127–e128

    Google Scholar 

  • Berezin AE (2017a) Contemporary approaches of biological markers in heart failure. Scholars’ Press, Omni Scriptum Management GmbH, Saarbrücken

    Google Scholar 

  • Berezin A (2017b) Does serum uric acid play a protective role against tissue damage in cardiovascular and metabolic diseases? Ann Clin Hypertens 1:39–41

    Article  Google Scholar 

  • Berezin A (2017c) Biomarkers in heart failure. J Blood Lymph 7(3):172–179

    Google Scholar 

  • Berezin A (2017d) Up-to-date clinical approaches of biomarkers’ use in heart failure. Biomed Res Ther 4(6):1341–1370

    Article  Google Scholar 

  • Berezin AE, Kremzer AA (2013) Serum uric acid as a marker of coronary calcification in patients with asymptomatic coronary artery disease with preserved left ventricular pump function. Cardiol Res Pract, Article ID 129369. https://doi.org/10.1155/2013/129369

  • Berezin AE, Samura TA (2013) Prognostic value of biological markers in myocardial infarction patients. Asian Cardiovasc Thorac Ann 21(2):142–150

    Article  CAS  PubMed  Google Scholar 

  • Berezin AE, Kremzer AA, Samura TA, Martovitskaya YV (2014a) Apoptotic microparticles to progenitor mononuclear cells ratio in heart failure: relevance of clinical status and outcomes. JCvD 2(2):50–57

    Google Scholar 

  • Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA (2014b) Serum uric acid predicts declining of circulating proangiogenic mononuclear progenitor cells in chronic heart failure patients. J Cardiovasc Thorac Res 6(3):153–162. https://doi.org/10.5681/jcvtr.2014.0XX

    Article  PubMed  PubMed Central  Google Scholar 

  • Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA, Zulli A et al (2015a) The utility of biomarker risk prediction score in patients with chronic heart failure. Int J Clin Exp Med 8(10):18255–18264

    PubMed  PubMed Central  CAS  Google Scholar 

  • Berezin AE, Kremzer AA, Berezina TA, Martovitskaya YV (2015b) Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: relevance to neurohumoral and inflammatory activation. BBA Clinical 4:69–75

    Article  PubMed  PubMed Central  Google Scholar 

  • Berezin AE, Kremzer AA, Samura TA (2015c) Circulating thrombospondine-2 in patients with moderate-to-severe chronic heart failure due to coronary artery disease. J Biomed Res 30. https://doi.org/10.7555/JBR.29.20140025. [Epub ahead of print]

  • Berezin A, Kremzer A, Martovitskaya Y, Samura T, Berezina T (2016) The novel biomarker risk prediction score in patients with chronic heart failure. Clin Hypertens 22(3). https://doi.org/10.1186/s40885-016-0041-1.

  • Besler C, Lang D, Urban D, Rommel KP, von Roeder M, Fengler K et al (2017a) Plasma and cardiac Galectin-3 in patients with heart failure reflects both inflammation and fibrosis: implications for its use as a biomarker. Circ Heart Fail 10(3). https://doi.org/10.1161/CIRCHEARTFAILURE.116.003804

    CAS  Google Scholar 

  • Besler C, Lang D, Urban D, Rommel KP, von Roeder M, Fengler K et al (2017b) Plasma and cardiac galectin-3 in patients with heart failure reflects both inflammation and fibrosis: implications for its use as a biomarker. Circ Heart Fail 10(3). https://doi.org/10.1161/CIRCHEARTFAILURE.116.003804

    CAS  Google Scholar 

  • Billebeau G, Vodovar N, Sadoune M, Launay JM, Beauvais F, Cohen-Solal A (2017) Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure. Eur J Prev Cardiol. https://doi.org/10.1177/2047487317705488. [Epub ahead of print]

  • Biomarkers Definitions Working Group (National Institutes of Health) (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95

    Article  Google Scholar 

  • Bondar G, Cadeiras M, Wisniewski N, Maque J, Chittoor J, Chang E et al (2014) Comparison of whole blood and peripheral blood mononuclear cell gene expression for evaluation of the perioperative inflammatory response in patients with advanced heart failure. PLoS One 9(12):e115097

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT et al (2015) Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 33:1729–1741

    Article  CAS  PubMed  Google Scholar 

  • Boulogne M, Sadoune M, Launay JM, Baudet M, Cohen-Solal A, Logeart D (2017a) Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol 226:53–59

    Article  CAS  PubMed  Google Scholar 

  • Boulogne M, Sadoune M, Launay JM, Baudet M, Cohen-Solal A, Logeart D (2017b) Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol 226:53–59

    Article  CAS  PubMed  Google Scholar 

  • Bustamante A, García-Berrocoso T, Penalba A, Giralt D, Simats A, Muchada M et al (2017) Sepsis biomarkers reprofiling to predict stroke-associated infections. J Neuroimmunol 312:19–23

    Article  CAS  PubMed  Google Scholar 

  • Chan MM, Santhanakrishnan R, Chong JP, Chen Z, Tai BC, Liew OW et al (2016) Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 18(1):81–88

    Article  CAS  PubMed  Google Scholar 

  • Chmurzynska A (2006) The multigene family of fatty acidbinding proteins (FABPs): function, structure, and polymorphism. J Appl Genet 47:39–48

    Article  PubMed  Google Scholar 

  • Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, Fonarow GC et al (2017) Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. https://doi.org/10.1161/CIR.0000000000000490. [Epub ahead of print]

  • Cohen-Solal A, Laribi S, Ishihara S, Vergaro G, Baudet M, Logeart D et al (2015) Prognostic markers of acute decompensated heart failure: the emerging roles of cardiac biomarkers and prognostic scores. Arch Cardiovasc Dis 108(1):64–74

    Article  PubMed  Google Scholar 

  • Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G et al (2011) Can emerging biomarkers of myocardial remodeling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 13(10):1087–1095

    Article  CAS  PubMed  Google Scholar 

  • Demissei BG, Cotter G, Prescott MF, Felker GM, Filippatos G, Greenberg BH et al (2017) A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. Eur J Heart Fail. https://doi.org/10.1002/ejhf.749. [Epub ahead of print]

  • Dres M, Hausfater P, Foissac F, Bernard M, Joly LM, Sebbane M et al (2017) Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study. Int J Chron Obstruct Pulmon Dis 12:1047–1056

    Article  PubMed  PubMed Central  Google Scholar 

  • Favresse J, Gruson D (2017) Natriuretic peptides: degradation, circulating forms, dosages and new therapeutic approaches. Ann Biol Clin (Paris). https://doi.org/10.1684/abc.2017.1235. [Epub ahead of print]

  • Fazakas Á, Szelényi Z, Szénási G, Nyírő G, Szabó PM, Patócs A et al (2016) Genetic predisposition in patients with hypertension and normal ejection fraction to oxidative stress. J Am Soc Hypertens 10(2):124–132

    Article  CAS  PubMed  Google Scholar 

  • Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N et al (2017) Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 318(8):713–720

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Feng SD, Jiang Y, Lin ZH, Lin PH, Lin SM, Liu QC (2017) Diagnostic value of brain natriuretic peptide and β-endorphin plasma concentration changes in patients with acute left heart failure and atrial fibrillation. Medicine (Baltimore) 96(34):e7526. https://doi.org/10.1097/MD.0000000000007526

    Article  CAS  Google Scholar 

  • Fonarow GC (2017) Biomarker-guided vs guideline-directed titration of medical therapy for heart failure. JAMA 318(8):707–708

    Article  PubMed  Google Scholar 

  • Friedrich FW, Dilanian G, Khattar P, Juhr D, Gueneau L, Charron P et al (2013) A novel genetic variant in the transcription factor Islet-1 exerts gain of function on myocyte enhancer factor 2C promoter activity. Eur J Heart Fail 15(3):267–276

    Article  CAS  PubMed  Google Scholar 

  • Ganna A, Rivadeneira F, Hofman A, Uitterlinden AG, Magnusson PK, Pedersen NL et al (2013) Genetic determinants of mortality. Can findings from genome-wide association studies explain variation in human mortality? Hum Genet 132(5):553–561

    Article  PubMed  Google Scholar 

  • Grassi D, Ferri L, Desideri G, Di Giosia P, Cheli P, Del Pinto R et al (2013) Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des 19:2432–2438

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hage C, Michaëlsson E, Linde C, Donal E, Daubert JC, Gan LM et al (2017) Inflammatory biomarkers predict heart failure severity and prognosis in patients with heart failure with preserved ejection fraction: a holistic proteomic approach. Circ Cardiovasc Genet 10(1). https://doi.org/10.1161/CIRCGENETICS.116.001633

    CAS  Google Scholar 

  • Hayashida K, Kondo Y, Hara Y, Aihara M, Yamakawa K (2017) Head-to-head comparison of procalcitonin and presepsin for the diagnosis of sepsis in critically ill adult patients: a protocol for a systematic review and meta-analysis. BMJ Open 7(3):e014305

    Article  PubMed  PubMed Central  Google Scholar 

  • Herrero-Puente P, Prieto-García B, García-García M, Jacob J, Martín-Sánchez FJ, Pascual-Figal D et al (2017) Predictive capacity of a multimarker strategy to determine short-term mortality in patients attending a hospital emergency department for acute heart failure. BIO-EAHFE study. Clin Chim Acta 466:22–30

    Article  CAS  PubMed  Google Scholar 

  • Hershberger RE, Siegfried JD (2011) Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 57(16):1641–1649

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hofman N, van Langen I, Wilde AAM (2010) Genetic testing in cardiovascular diseases. Curr Opin Cardiol 25(3):243–248

    Article  PubMed  Google Scholar 

  • Huerta A, López B, Ravassa S, San José G, Querejeta R, Beloqui Ó et al (2016) Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. J Hypertens 34(1):130–138

    Article  CAS  PubMed  Google Scholar 

  • Hutchinson KR, Stewart JA Jr, Lucchesi PA (2010) Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol 48(3):564–569

    Article  CAS  PubMed  Google Scholar 

  • Imran TF, Shin HJ, Mathenge N, Wang F, Kim B, Joseph J et al (2017) Meta-analysis of the usefulness of plasma Galectin-3 to predict the risk of mortality in patients with heart failure and in the general population. Am J Cardiol 119(1):57–64

    Article  CAS  PubMed  Google Scholar 

  • Jin P, Gu W, Lai Y, Zheng W, Zhou Q, Wu X (2017) The circulating MicroRNA-206 level predicts the severity of pulmonary hypertension in patients with left heart diseases. Cell Physiol Biochem 41(6):2150–2160

    Article  CAS  PubMed  Google Scholar 

  • Kempf T, Wollert KC (2009) Growth differentiation Factor-15: a new biomarker in cardiovascular disease. Herz 34:594–599

    Article  PubMed  Google Scholar 

  • Kim H, Yoon HJ, Park HS, Cho YK, Nam CW, Hur SH et al (2013) Potentials of cystatin C and uric acid for predicting prognosis of heart failure. Congest Heart Fail 19(3):123–129

    Article  CAS  PubMed  Google Scholar 

  • Kim TH, Kim H, Kim IC (2015) The potential of cystatin-C to evaluate the prognosis of acute heart failure: a comparative study. Acute Card Care 17(4):72–76

    Article  PubMed  Google Scholar 

  • Kitai T, Kim YH, Kiefer K, Morales R, Borowski AG, Grodin JL et al (2017) Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure. Clin Biochem. https://doi.org/10.1016/j.clinbiochem.2017.02.014. [Epub ahead of print]

  • Kolder IC, Michels M, Christiaans I, Ten Cate FJ, Majoor-Krakauer D, Danser AH et al (2012) The role of renin-angiotensin-aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy. Eur J Hum Genet 20(10):1071–1077

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Krane V, Genser B, Kleber ME, Drechsler C, März W, Delgado G et al (2017) Copeptin associates with cause-specific mortality in patients with impaired renal function: results from the LURIC and the 4D study. Clin Chem. https://doi.org/10.1373/clinchem.2016.266254. [Epub ahead of print]

  • Krintus M, Kozinski M, Fabiszak T, Kubica J, Panteghini M, Sypniewska G (2017) Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. Clin Biochem. https://doi.org/10.1016/j.clinbiochem.2017.03.015. [Epub ahead of print]

  • Lala RI, Lungeanu D, Darabantiu D, Pilat L, Puschita M (2017) Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure. Herz. https://doi.org/10.1007/s00059-017-4538-5. [Epub ahead of print]

  • Ledwidge M, Gallagher J, Conlon C, Tallon E, O’Connell E, Dawkins I et al (2013) Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 310:66–74

    Article  CAS  PubMed  Google Scholar 

  • Löfsjögård J, Persson H, Díez J, López B, González A, Edner M et al (2014) Atrial fibrillation and biomarkers of myocardial fibrosis in heart failure. Scand Cardiovasc J 48(5):299–303

    Article  CAS  PubMed  Google Scholar 

  • Löfsjögård J, Kahan T, Díez J, López B, González A, Ravassa S et al (2017) Usefulness of collagen Carboxy-terminal propeptide and telopeptide to predict disturbances of long-term mortality in patients ≥60 years with heart failure and reduced ejection fraction. Am J Cardiol. https://doi.org/10.1016/j.amjcard.2017.03.036. [Epub ahead of print]

  • Lopes LR, Elliott PM (2013) Genetics of heart failure. BBA Mol Basis Dis 1832(12):2451–2461

    Article  CAS  Google Scholar 

  • Lopes D, Menezes Falcão L (2017) Mid-regional pro-adrenomedullin and ST2 in heart failure: contributions to diagnosis and prognosis. Rev Port Cardiol 36(6):465–472

    Article  PubMed  Google Scholar 

  • Luchner A, von Haehling S, Holubarsch C, Keller T, Knebel F, Zugck C et al (2017) Indications and clinical implications of the use of the cardiac markers BNP and NT-proBNP. Dtsch Med Wochenschr 142(5):346–355

    Article  PubMed  Google Scholar 

  • Maisel AS, Di Somma S (2016) Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2). Eur Heart J. https://doi.org/10.1093/eurheartj/ehw462. [Epub ahead of print]

  • Malek V, Gaikwad AB (2017) Neprilysin inhibitors: a new hope to halt the diabetic cardiovascular and renal complications? Biomed Pharmacother 90:752–759

    Article  CAS  PubMed  Google Scholar 

  • Masson S, Latini R, Anand IS (2010) An update on cardiac troponins as circulating biomarkers in heart failure. Curr Heart Fail Rep 7(1):15–21

    Article  CAS  PubMed  Google Scholar 

  • McNamara DM, Taylor AL, Tam SW, Worcel M, Yancy CW, Hanley-Yanez K et al (2014) G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT. JACC Heart Fail 2(6):551–557

    Article  PubMed  Google Scholar 

  • Meijers WC, van der Velde AR, Muller Kobold AC, Dijck-Brouwer J, AH W, Jaffe A et al (2017) Variability of biomarkers in patients with chronic heart failure and healthy controls. Eur J Heart Fail 19(3):357–365

    Article  CAS  PubMed  Google Scholar 

  • Miró Ò, González de la Presa B, Herrero-Puente P, Fernández Bonifacio R, Möckel M, Mueller C et al (2017) The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure. Biomarkers 2:1–9. https://doi.org/10.1080/1354750X.2017.1319421.

    Article  Google Scholar 

  • Moayedi Y, Ross HJ (2017) Advances in heart failure: a review of biomarkers, emerging pharmacological therapies, durable mechanical support and telemonitoring. Clin Sci (Lond) 131(7):553–566

    Article  CAS  Google Scholar 

  • Morgenthaler NG (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112–119

    Article  CAS  PubMed  Google Scholar 

  • Mozos I, Marginean O (2015) Links between vitamin D deficiency and cardiovascular diseases. Biomed Res Int 2015:109275. https://doi.org/10.1155/2015/109275

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Mozos I, Stoian D, Luca CT (2017) Crosstalk between vitamin A, B12, D, K, C and E status and arterial stiffness. Dis Markers 2017:8784971. https://doi.org/10.1155/2017/8784971

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Nagarajan V, Hernandez AV, Tang WH (2012) Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart 98(24):1778–1786

    Article  PubMed  Google Scholar 

  • Nakanishi M, Nakao K, Kumasaka L, Arakawa T, Fukui S, Ohara T et al (2017) Improvement in exercise capacity by exercise training associated with favorable clinical outcomes in advanced heart failure with high B-type natriuretic peptide level. Circ J. https://doi.org/10.1253/circj.CJ-16-1268. [Epub ahead of print]

  • Nelveg-Kristensen KE, Busk Madsen M, Torp-Pedersen C, Køber L, Egfjord M, Berg Rasmussen H et al (2015) Pharmacogenetic risk stratification in angiotensin-converting enzyme inhibitor-treated patients with congestive heart failure: a retrospective cohort study. PLoS One 10(12):e0144195

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nymo SH, Aukrust P, Kjekshus J, McMurray JJ, Cleland JG, Wikstrand J et al (2017) CORONA study group. Limited added value of circulating inflammatory biomarkers in chronic heart failure. JACC Heart Fail 5(4):256–264. https://doi.org/10.1016/j.jchf.2017.01.008.

    Article  PubMed  Google Scholar 

  • Odermatt J, Meili M, Hersberger L, Bolliger R, Christ-Crain M, Briel M et al (2017) Pro-Adrenomedullin predicts 10-year all-cause mortality in community-dwelling patients: a prospective cohort study. BMC Cardiovasc Disord 17(1):178

    Article  PubMed  PubMed Central  Google Scholar 

  • Okazaki H, Shirakabe A, Kobayashi N, Hata N, Shinada T, Matsushita M et al (2016) The prognostic impact of uric acid in patients with severely decompensated acute heart failure. J Cardiol 68(5):384–391

    Article  PubMed  Google Scholar 

  • Okazaki H, Shirakabe A, Kobayashi N, Hata N, Shinada T, Matsushita M et al (2017) Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia. Heart Vessel 32(4):436–445

    Article  Google Scholar 

  • Otaki Y, Watanabe T, Kinoshita D, Yokoyama M, Takahashi T, Toshima T et al (2017) Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure. Int J Cardiol 228:151–157

    Article  PubMed  Google Scholar 

  • Poller W, Dimmeler S, Heymans S, Zeller T, Haas J, Karakas M et al (2017) Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur Heart J. https://doi.org/10.1093/eurheartj/ehx165. [Epub ahead of print]

  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Authors/Task Force Members et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200

    Article  Google Scholar 

  • Pouleur AC (2015) Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction? Clin Chim Acta 443:9–16

    Article  CAS  PubMed  Google Scholar 

  • Qian HY, Huang J, Yang YJ, Yang YM, Li ZZ, Zhang JM (2016) Heart-type fatty acid binding protein in the assessment of acute pulmonary embolism. Am J Med Sci 352(6):557–562

    Article  PubMed  Google Scholar 

  • Reiner MM, Khoury WE, Canales MB, Chmielewski RA, Patel K, Razzante MC et al (2017) Procalcitonin as a biomarker for predicting amputation level in lower extremity infections. J Foot Ankle Surg. https://doi.org/10.1053/j.jfas.2017.01.014. [Epub ahead of print]

  • Remde H, Dietz A, Emeny R, Riester A, Peters A, de Las Heras Gala T et al (2016) The cardiovascular markers copeptin and high-sensitive C-reactive protein decrease following specific therapy for primary aldosteronism. J Hypertens 34:2066–2073

    Article  CAS  PubMed  Google Scholar 

  • Ryu JA, Yang JH, Lee D, Park CM, Suh GY, Jeon K et al (2015) Clinical usefulness of procalcitonin and C-reactive protein as outcome predictors in critically ill patients with severe sepsis and septic shock. PLoS One 10(9):e0138150

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sahin I, Gungor B, Ozkaynak B, Uzun F, Küçük SH, Avci II et al (2017) Higher copeptin levels are associated with worse outcome in patients with hypertrophic cardiomyopathy. Clin Cardiol 40(1):32–37

    Article  PubMed  Google Scholar 

  • Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Simic D, Radovanovic S, Simic T (2017) Novel biomarkers of heart failure. Adv Clin Chem 79:93–152

    Article  CAS  PubMed  Google Scholar 

  • Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217

    Article  CAS  PubMed  Google Scholar 

  • Skaf S, Thibault B, Khairy P, O’Meara E, Fortier A, Vakulenko HV, EARTH Investigators et al (2017) Impact of left ventricular vs biventricular pacing on reverse remodelling: insights from the evaluation of resynchronization therapy for heart failure (EARTH) trial. Can J Cardiol 33(10):1274–1282

    Article  PubMed  Google Scholar 

  • Smaradottir MI, Ritsinger V, Gyberg V, Norhammar A, Näsman P, Mellbin LG (2017) Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities – a marker of increased stress susceptibility? A report from the glucose in acute myocardial infarction cohort. Diab Vasc Dis Res 14(2):69–76

    Article  CAS  PubMed  Google Scholar 

  • Souza BSF, Silva DN, Carvalho RH, Sampaio GLA, Paredes BD, Aragão França L et al (2017) Association of cardiac galectin-3 expression, myocarditis, and fibrosis in chronic chagas disease cardiomyopathy. Am J Pathol 187(5):1134–1146

    Article  CAS  PubMed  Google Scholar 

  • Srivatsan V, George M, Shanmugam E (2015) Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? Eur J Prev Cardiol 22(9):1096–1110

    Article  PubMed  Google Scholar 

  • Sutter ME, Gaedigk A, Albertson TE, Southard J, Owen KP, Mills LD et al (2013) Polymorphisms in CYP2D6 may predict methamphetamine related heart failure. Clin Toxicol (Phila) 51(7):540–544

    Article  CAS  Google Scholar 

  • Taub PR, Borden KC, Fard A, Maisel A (2012) Role of biomarkers in the diagnosis and prognosis of acute kidney injury in patients with cardiorenal syndrome. Expert Rev Cardiovasc Ther 10(5):657–667

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Teekakirikul P, Kelly MA, Rehm HL, Lakdawala NK, Funke BH (2013) Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. J Mol Diagn 15(2):158–170

    Article  PubMed  Google Scholar 

  • Teo LY, Moran RT, Tang WH (2015) Evolving approaches to genetic evaluation of specific cardiomyopathies. Curr Heart Fail Rep 12(6):339–349

    Article  PubMed  Google Scholar 

  • Tziakas DN, Chalikias GK, Stakos D, Chatzikyriakou SV, Papazoglou D, Mitrousi K et al (2012) Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. Eur J Prev Cardiol 19(1):62–71

    Article  PubMed  Google Scholar 

  • Vegter EL, van der Meer P, Voors AA (2017) Associations between volume status and circulating microRNAs in acute heart failure. Eur J Heart Fail. https://doi.org/10.1002/ejhf.867. [Epub ahead of print]

  • Welsh P, Kou L, Yu C, Anand I, van Veldhuisen DJ, Maggioni AP et al (2017) Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. Eur J Heart Fail. https://doi.org/10.1002/ejhf.988. [Epub ahead of print]

  • Wettersten N, Maisel AS (2016) Biomarkers for heart failure: an update for practitioners of internal medicine. Am J Med 129(6):560–567

    Article  CAS  PubMed  Google Scholar 

  • Wojciechowska C, Romuk E, Nowalany-Kozielska E, Jacheć W (2017) Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients. Hell J Cardiol. https://doi.org/10.1016/j.hjc.2017.03.006. [Epub ahead of print]

  • Wong CM, Hawkins NM, Petrie MC, Jhund PS, Gardner RS, Ariti CA, MAGGIC Investigators et al (2014) Heart failure in younger patients: the meta-analysis global Group in Chronic Heart Failure (MAGGIC). Eur Heart J 35(39):2714–2721

    Article  PubMed  Google Scholar 

  • Wong PC, Guo J, Zhang A (2017) The renal and cardiovascular effects of natriuretic peptides. Absence of clear clinical recommendations of biomarker-based HF therapy is the main cause of uncertainty regarding practical use of this approach. Adv Physiol Educ 41(2):179–185. https://doi.org/10.1152/advan.00177.2016

    Article  PubMed  Google Scholar 

  • Wu CK, Luo JL, XM W, Tsai CT, Lin JW, Hwang JJ et al (2009) A propensity score-based case-control study of renin-angiotensin system gene polymorphisms and diastolic heart failure. Atherosclerosis 205(2):497–502

    Article  CAS  PubMed  Google Scholar 

  • Wu CK, Luo JL, Tsai CT, Huang YT, Cheng CL, Lee JK et al (2010) Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. Pharmacogenomics J 10(1):46–53

    Article  CAS  PubMed  Google Scholar 

  • Yan JJ, Lu Y, Kuai ZP, Yong YH (2017a) Predictive value of plasma copeptin level for the risk and mortality of heart failure: a meta-analysis. J Cell Mol Med. https://doi.org/10.1111/jcmm.13102. [Epub ahead of print]

  • Yan H, Ma F, Zhang Y, Wang C, Qiu D, Zhou K et al (2017b) miRNAs as biomarkers for diagnosis of heart failure: a systematic review and meta-analysis. Medicine (Baltimore) 96(22):e6825. https://doi.org/10.1097/MD.0000000000006825

    Article  CAS  Google Scholar 

  • Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM et al (2017) ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Card Fail. https://doi.org/10.1016/j.cardfail.2017.04.014. [Epub ahead of print]

  • Yang J, Xu WW, Hu SJ (2015) Heart failure: advanced development in genetics and epigenetics. Biomed Res Int 2015:352734

    PubMed  PubMed Central  Google Scholar 

  • Yip VL, Pirmohamed M (2013) Expanding role of pharmacogenomics in the management of cardiovascular disorders. Am J Cardiovasc Drugs 13(3):151–162

    Article  CAS  PubMed  Google Scholar 

  • Yu B, Zheng Y, Alexander D, Manolio TA, Alonso A, Nettleton JA et al (2013) Genome-wide association study of a heart failure related metabolomic profile among African Americans in the Atherosclerosis Risk in Communities (ARIC) study. Genet Epidemiol 37(8):840–845

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicts of Interest

Not declared.

Author information

Authors and Affiliations

  1. Internal Medicine Department, State Medical University of Zaporozhye, Zaporozhye, Ukraine

    Alexander E. Berezin

Authors
  1. Alexander E. Berezin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander E. Berezin .

Editor information

Editors and Affiliations

  1. Department of Clinical Sciences and Education, Karolinska Institutet, Stockholm, Sweden

    Md. Shahidul Islam

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Berezin, A.E. (2018). Circulating Biomarkers in Heart Failure. In: Islam, M. (eds) Heart Failure: From Research to Clinical Practice. Advances in Experimental Medicine and Biology(), vol 1067. Springer, Cham. https://doi.org/10.1007/5584_2017_140

Download citation

  • DOI: https://doi.org/10.1007/5584_2017_140

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-78279-9

  • Online ISBN: 978-3-319-78280-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation